IQE plc has completed an £81 million fundraising, securing strategic investment and board appointments from key customer MACOM.
Fundraising details
The Cardiff-based epiwafer and substrate manufacturer raised total subscription proceeds of £81 million. Admission of 332,183,678 new shares is expected on or around 1 June 2026.
Following admission, IQE’s issued share capital will comprise 1,312,590,972 ordinary shares of 1 pence each, with 4,115 shares held in treasury. The total voting rights figure stands at 1,312,586,857, which shareholders should use as the denominator for disclosure notifications under FCA rules.
Strategic board appointments
IQE is in the process of appointing Robert Dennehy and David O’Carroll as non-executive directors. Dennehy serves as chief operating officer and O’Carroll as vice president at MACOM Technology Solutions Inc, a customer based in Lowell, Massachusetts.
Pending completion of Nomad due diligence and formal appointments, IQE has entered a side letter granting the investor limited consent rights. This arrangement ties the fundraising directly to strengthening the customer relationship.
Manufacturing implications
The £81 million raise follows IQE’s earlier announcement of £45 million in long-term supply agreements with MACOM. The capital injection will likely support capacity expansion and R&D for advanced epitaxial wafers used in RF, photonics, and power semiconductor applications.
IQE’s position as a leading independent epiwafer supplier is reinforced by this strategic alignment with a major customer. The board appointments signal deeper integration between IQE and MACOM’s supply chain.
Forward outlook
This fundraising positions IQE to scale production in high-growth compound semiconductor markets. The combination of capital and customer board representation suggests a long-term partnership model that could become a template for other epiwafer suppliers seeking to de-risk demand while financing capital-intensive manufacturing.
